jeudi 04 juin 2020

L’ANR soutient les recherches à court terme sur le Covid-19


 

L'Agence nationale de la recherche lance un nouvel appel pour soutenir des projets de type recherche-action RA-Covid-19 dont les résultats pourraient être diffusés à la société dans les trois à douze prochains mois.

Pour assurer sa réactivité, cet appel qui prolonge l'appel Flash Covid-19, sera ouvert en continu jusqu'au 28 octobre 2020

 

Conformément aux recommandations de l'Organisation mondiale de la Santé, les thématiques de l'appel concernent :

  • les études épidémiologiques,
  • la physiopathogénie de la maladie,
  • la prévention et contrôle de l'infection,
  • l'éthique et dynamiques sociales,
  • les enjeux globaux de l'épidémie Covid-19.

Pour permettre un financement rapide des propositions, la sélection sera opérée au fil de l'eau.

 

L'ouverture du site de dépôt des projets est prévue le 20 avril 2020.

 

https://intranet.inserm.fr/actualites/Pages/detail.aspx?news_id=301

https://anr.fr/fr/detail/call/appel-a-projets-ra-covid-19/

jeudi 04 juin 2020

DIM ELICIT: Special Call SARS-CoV-2


 

The DIM ELICIT would like to support projects developing innovative technologies and methods regarding the analysis, diagnosis and / or treatment to fight SARS-CoV-2.

 

Any research team from the region Ile de France can apply with a project linked to the infectious agent SARS-CoV-2, and in accordance with the DIM ELICIT’s goals, positioning and thematic axes.

 

In the context of this call, the DIM ELICIT will fund each project:

- 15k€ for running and / or staff costs

and / or

- 30k€ of equipment

(66% max of total cost without VAT).

 

The projects submitted must target the acquisition of knowledge with a potential impact expected within 18 months following the funding.

 

This call will be open until the end of the crisis.

 

We will acknowledge the receipt of the applications within two days and try to give you a feedback on your eligibility within a week.

For more information and the application form, please see the link:
Special call for proposals - Fight SARS-CoV-2

https://dim-elicit.fr/appels-a-projets/

 

For any further question, do not hesitate to contact:
axel.bonetto@pasteur.fr or dim.elicit@pasteur.fr

samedi 04 juillet 2020

Partenariats public-privés pour la recherche contre le Covid-19


BPI France finance jusqu'à 50 millions d'euros des travaux de recherche et développement qui associent des industriels et leurs partenaires publics, dans le cadre de la lutte contre l'épidémie de Covid-19.

 

Ce programme propose de soutenir des projets collaboratifs de recherche et développement structurants visant le développement de solutions thérapeutiques à visée préventive ou curative contre le COVID-19. Des retombées économiques et technologiques directes sous forme de nouveaux produits, services et technologies, sont attendues. Toutes les stratégies thérapeutiques sont éligibles (vaccinales, antivirales, mixtes, etc.) ainsi que toutes les technologies (chimie, biotechnologie, intelligence artificielle et exploitation de données massives ou dispositif médical si pertinent).

 

Date limite de candidature 30 septembre 2020.
+ d'infos : https://www.bpifrance.fr/A-la-une/Appels-a-projets-concours/PSPC-COVID-19-49161

dimanche 05 juillet 2020

Faculté SANTE de Université de Paris - Appel à projets Animations Scientifiques



La Faculté Santé vous informe du lancement d’un Appel à Projets pour soutenir les animations scientifiques au sein de la Faculté Santé de Université de Paris.

Une enveloppe budgétaire de 100k€ est réservée pour soutenir cette action pour l’année 2020.

Tous les enseignants−chercheurs et chercheurs appartenant à une unité de recherche rattachée à la Faculté Santé de Université de Paris sont éligibles.
Vous trouverez ci-joint les informations pour déposer un projet.

La date limite de soumission est fixée au 5 juillet 2020.

vendredi 10 juillet 2020

Alzheimer Drug Discovery Foundation: Neuroimaging and CSF Biomarker Development RFP


The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias.

  • Specifically, this RFP focuses on:
  • developing novel PET ligands for clinical use
  • supporting novel CSF biomarkers
  • validating established MRI approaches in larger cohorts

Peripheral biofluids and digital approaches are supported through the Diagnostics Accelerator RFP.

Novel biomarkers of neuroinflammation and synaptic integrity are considered high priority. Other target areas of interest include:

  • Neuronal loss
  • Vascular injury and blood-brain barrier integrity
  • Mitochondria and metabolic function
  • Protein misfolding/proteostasis
  • Oxidative stress
  • White matter changes

Other novel targets supported by compelling biological rationale and connection to disease

The ADDF has limited interest in CSF measures of amyloid and tau.

 

Deadlines:

 

Letter of Intent

Invited Full Proposal

April 10, 2020

May 8, 2020

July 10, 2020

August 7, 2020

October 9, 2020

November 6, 2020

 

Average Award:

Up to $600,000 based on stage and scope of research.

Average Duration:

One year with potential for follow-on funding.
Multi-year proposals can be considered.

Funding priorities:

The ADDF focuses on supporting drug development for Alzheimer’s and related dementias and the biomarker tools that aid in this process. This RFP prioritizes biomarker programs that define a specific use and have potential for commercial and clinical translation, with an emphasis on clinical trials. The RFP supports advancement of neuroimaging and CSF biomarkers that can do one or more of the following:

Demonstrate target engagement for novel therapeutics

Detect signs of disease earlier and monitor progression

More accurately diagnose and distinguish between dementia subtypes

 

https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers

vendredi 31 juillet 2020

Financial support to the organization of scientific events


 

 

More information : please download the document

samedi 01 août 2020

The Focused Ultrasound Foundation


 

We fund high risk or clinically based investigator-initiated projects through the External Awards Program. We also fund projects in high-priority applications of FUS through the Brain Program, Cancer Immunotherapy Program, and Veterinary Program, including both invited and investigator-initiated projects.

Brain program: It is the ultimate goal of the Foundation's Brain Program to see focused ultrasound become a standard of care for the treatment of a range of neurological disorders, including movement disorders, brain tumors, epilepsy and stroke.

 

The External Awards Program provides funding for investigator-initiated clinical, preclinical, and early-stage research projects through a competitive peer-reviewed application process.

 

The program has two tracks:

* The Pre-Clinical Track is geared primarily towards preclinical studies and research projects that target a particular clinical indication or organ. It is meant to fund research that could lead the way to a new reimbursable clinical application for image-guided FUS within five to seven years.

 

*The High-Risk Track is intended for early-stage, high-risk, proof-of-concept research that, if successful, could have a profound impact on the field of focused ultrasound and that could change the way many conditions are treated.

 

**Additionally, the External Awards Program accepts abstracts for Clinical Trial funding requests. The abstract form for Clinical Trials is linked in the Materials section below. Funding for clinical trials is not limited to $100,000 and one year.

 

Funding: one-year awards totaling approximately $100,000

The Pre-Clinical Track typically does not fund large capital purchases, cannot fund overhead or institutional expenses, and will not fund the development of new focused ultrasound equipment

 

Application Process

Step 1: A one-page Research Abstract must be submitted at least two weeks prior to the program’s quarterly application deadlines (Feb. 1, May 1, Aug. 1, and Nov. 1).

Step 2: The Foundation will invite full Research Proposals from authors of approved Research Abstracts.

Funding decisions are returned to the applicant approximately three months after their application deadline.

 

https://fusfoundation.org/for-researchers/external-research-awards-program/apply-for-funding

https://fusfoundation.org/for-researchers/external-research-awards-program

 

Questions?

Please contact Matt Eames, PhD, Director of External Research, at meames@fusfoundation.org.

 

 

mercredi 02 septembre 2020

Appels à proposition de l'Inserm pour un séminaire scientifique franco-japonais


 

L'Inserm et la Japan Society for the Promotion of Science soutiennent les candidats à l'organisation en France, en 2021, d'un séminaire conjoint sur le thème des sciences de la vie et de la santé. Date limite de dépôt des propositions : 2 septembre 2020.

+ d'infos : Intranet Inserm

lundi 07 septembre 2020

Appels à proposition de l'Inserm


 

L'Inserm lance deux appels à propositions pour soutenir les coopérations internationales
Avec les projets "Tremplin international", les équipes Inserm bénéficieront de 10 000 € pour explorer des pistes de collaboration avec une équipe étrangère.​ Avec le dispositif "Projet de recherche international", l'Institut soutient jusqu'à 75 000 € des partenariats émergents ou déjà existants.​

Date limite de candidature : 7 septembre 2020.

+ d'infos : Intranet Inserm (Support à la recherche, Trouver un financement, Appels à proposition de l'Inserm)

lundi 14 septembre 2020

Interventions, services et politiques favorables à la santé


 

L'Institut de recherche en santé publique et ses partenaires lancent leur appel à projets 2020.

Date limite de candidature : 14 septembre 2020.


https://www.iresp.net/financements/appel-a-projets-general-2020/

lundi 14 septembre 2020

Fédération pour la Recherche sur le Cerveau : Appel à projets exceptionnel 2021 « Rotary- Espoir en Tête » 2021


La Fédération pour la Recherche sur le Cerveau lance son appel à projets exceptionnel visant à soutenir des projets de recherche portant sur des questions générales en neurosciences, ou en relation avec les pathologies neurologiques ou psychiatriques.

Cet appel à projets est organisé à l’occasion de l’opération “Rotary – Espoir en Tête 2021 ” dans le cadre du partenariat entre la FRC et les Rotariens français. Il servira exclusivement à financer ou cofinancer l’achat d’un équipement important (soit un appareil unique, soit une somme de matériels constituant un appareil unique) pouvant faire l’objet d’une utilisation commune à plusieurs équipes (mutualisation de moyens). Dans les cas de co-financements, les apports provenant d’autres sources (non liées à l’opération “Rotary – Espoir en tête”) ne devront en aucun cas excéder 20% du montant total du prix d‘acquisition du matériel. Plusieurs projets, pour des montants compris entre 80 000€ et 200 000€ chacun, pourront être financés dans le cadre du présent appel à projets. Ils pourront être présentés par une ou plusieurs équipes souhaitant poursuivre ou entreprendre une collaboration.

Procédure de candidature :

Phase 1 : Soumission du dossier d’intention (email et papier) avant le vendredi 13 mars 2020 à minuit (cachet de la poste faisant foi).

Phase 2 : Les candidatures présélectionnées présenteront un projet détaillé. Ce dossier devra parvenir à la FRC (email et papier) au plus tard le 14 septembre 2020 à minuit.

https://www.frcneurodon.org/informer-sur-la-recherche/appels-a-projet-en-cours/candidater/?cn-reloaded=1

jeudi 17 septembre 2020

Funding opportunities from International Foundations


On this page discover the funding opportunities of international foundations according to your activity topics

 

Below the exel version

jeudi 17 septembre 2020

NIH Funding Opportunities


NIH Funding Opportunities (Foreign Institutions are eligible to apply) / Financements NIH ouverts aux institutions non-US

Ensemble d'appels d'offres ouverts aux institutions non-US, on this page, a set of calls for proposals that are open to non-US institutions

dimanche 20 septembre 2020

France Parkinson : Grand appel d'offres exceptionnel


 

FRANCE PARKINSON met au concours des projets multicentriques dans le but de permettre à des équipes de réaliser de grands projets collaboratifs cliniques et/ou translationnels impliquant plusieurs sites et/ou pays et/ou disciplines. Un site français porteur du projet sera indispensable.

Cette dotation favorisera les recherches concernant l’étiologie, la physiopathologie, l’évolution, le traitement et la prise en charge de la maladie de Parkinson.

Les demandes de financement devront être comprises en 100 000 et 500 000€.

Les fonds pourront couvrir :

  • Les frais de fonctionnement.
  • Rémunération ou Salaire [au maximum 30% du montant total demandé].
  • L’achat d’équipement nécessaire à la recherche [au maximum 10% du montant total demandé].
  • Les frais de mission ET de publication [au maximum 10% du montant total demandé].

La durée du projet sera limitée à 3-5ans. Les dossiers devront être soumis exclusivement en anglais pour en faciliter l’expertise internationale.

Date limite de réception des lettres d’intention : 17 mars 2020

Réception des dossiers complets : 20 septembre 2020                                                

 

https://www.franceparkinson.fr/wp-content/uploads/2020/01/APPEL-A-PROJETS-GAO-2020.pdf

lundi 28 septembre 2020

American Epilepsy Society (AES): Seed Grant for established investigators


In partnership with our rare disease partners offer seed funding to help established investigators launch new lines of research, collaborations, and/or research methods.

Seed grants provide up to $20,000 for one year, to be used to cover direct costs to fund preliminary investigation that will help researchers compete for larger grants that cover the full cost of research. They may not be renewed.

Current Round Deadlines:

April 3, 2020.

September 28, 2020

Eligibility Criteria: Preference will be given to applications for research to be conducted at U.S. institutions. Depending on available funds, applications may be considered from investigators outside the U.S. who otherwise meet the eligibility criteria.

https://www.aesnet.org/research/funding%20for%20established%20investigators/seed_grant_program

mardi 29 septembre 2020

Innovative Medicines Intiative IMI2 23rd Call, Topic 3


 A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases (Topic code: IMI2-2020-23-03)

The Innovative Medicines Initiative is a jointly fund

 A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases (Topic code: IMI2-2020-23-03)

The Innovative Medicines Initiative is a jointly funded partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Indicative budget:

    From EFPIA companies and IMI2 Associated Partners: EUR 47 360 000

    From the IMI2 JU: EUR 47 790 000

Key dates and deadlines:

    Draft topic texts published: 6 April 2020

    Publication date: 23 June 2020

    Stage 1 submission start date: 23 June 2020

    Stage 1 submission deadline: 29 September 2020 (17:00 Brussels time)

    Stage 2 submission deadline: 17 March 2021 (17:00 Brussels time)

 

Objectives in the scope of this topic:

  1. Create a set of agreed principles to enable sharing and access to data and samples, taking into consideration all the established legal and ethical research standards and principles (e.g. General Data Protection Regulation (GDPR), legal, intellectual property (IP), ethical, regulatory, societal issues) and their practical implementation.

  2. Establish a network that can house high quality data and samples, which could have federated and centralised elements. This must build on existing ongoing and relevant cohorts (see objective 4). The overall solution has to be interoperable (e.g. with other global data platforms), scalable and suitable for a broad variety of both data types (including digital), and samples, from public and private (e.g. proprietary clinical trials) sources, whether they be part of the consortium or provided from external donors. Activities related to building a biorepository or data management and sharing platform from scratch are out of scope for this topic. Instead, these must build upon existing resources (including ongoing longitudinal cohorts or studies), knowledge and infrastructures to deliver a novel solution able for seamlessly incorporating existing retrospective samples and data with prospective samples and data collections.

  3. Establish fair and transparent governance and processes specifically to enable sharing and access to data and samples.

  4. Test the above with the defined case studies and apply the learnings to fine-tune processes and use the outcomes to grow the platform. Case studies need to include (but are not limited to) the amyloid-tau-neurodegeneration (ATN) system (in cohorts with early Alzheimer’s disease) and the complement pathway (in Parkinson’s disease). Applicants have to include the well substantiated description of:
  • cohorts with early Alzheimer’s disease, which will allow the evaluation of the ATN system, comparing more complex and expensive markers like cerebrospinal fluid amyloid β (Aβ) & tau, amyloid-positron emission tomography (PET) and magnetic resonance imaging (MRI) with potential liquid biopsy (blood, saliva,..) markers as alternate biomarkers and;
  • cohorts with Parkinson’s disease to investigate the impact/relation of the complement system on diagnosis, severity and progression. This should be especially in light of new classes of minimally invasive neurodegenerative disease biomarkers (e.g. autoantibodies, DNA methylation, exosomes) and sample matrices (e.g. saliva).
  1. This platform must be a self-sustainable entity by the end of the project.

 More information: IMI2_Call23_CallText

https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-23

ed partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Indicative budget:

    From EFPIA companies and IMI2 Associated Partners: EUR 47 360 000

    From the IMI2 JU: EUR 47 790 000

Key dates and deadlines:

    Draft topic texts published: 6 April 2020

    Publication date: 23 June 2020

    Stage 1 submission start date: 23 June 2020

    Stage 1 submission deadline: 29 September 2020 (17:00 Brussels time)

    Stage 2 submission deadline: 17 March 2021 (17:00 Brussels time)

 

Objectives in the scope of this topic:

  1. Create a set of agreed principles to enable sharing and access to data and samples, taking into consideration all the established legal and ethical research standards and principles (e.g. General Data Protection Regulation (GDPR), legal, intellectual property (IP), ethical, regulatory, societal issues) and their practical implementation.

  2. Establish a network that can house high quality data and samples, which could have federated and centralised elements. This must build on existing ongoing and relevant cohorts (see objective 4). The overall solution has to be interoperable (e.g. with other global data platforms), scalable and suitable for a broad variety of both data types (including digital), and samples, from public and private (e.g. proprietary clinical trials) sources, whether they be part of the consortium or provided from external donors. Activities related to building a biorepository or data management and sharing platform from scratch are out of scope for this topic. Instead, these must build upon existing resources (including ongoing longitudinal cohorts or studies), knowledge and infrastructures to deliver a novel solution able for seamlessly incorporating existing retrospective samples and data with prospective samples and data collections.

  3. Establish fair and transparent governance and processes specifically to enable sharing and access to data and samples.

  4. Test the above with the defined case studies and apply the learnings to fine-tune processes and use the outcomes to grow the platform. Case studies need to include (but are not limited to) the amyloid-tau-neurodegeneration (ATN) system (in cohorts with early Alzheimer’s disease) and the complement pathway (in Parkinson’s disease). Applicants have to include the well substantiated description of:
  • cohorts with early Alzheimer’s disease, which will allow the evaluation of the ATN system, comparing more complex and expensive markers like cerebrospinal fluid amyloid β (Aβ) & tau, amyloid-positron emission tomography (PET) and magnetic resonance imaging (MRI) with potential liquid biopsy (blood, saliva,..) markers as alternate biomarkers and;
  • cohorts with Parkinson’s disease to investigate the impact/relation of the complement system on diagnosis, severity and progression. This should be especially in light of new classes of minimally invasive neurodegenerative disease biomarkers (e.g. autoantibodies, DNA methylation, exosomes) and sample matrices (e.g. saliva).
  1. This platform must be a self-sustainable entity by the end of the project.

 More information: IMI2_Call23_CallText

https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-23

mercredi 30 septembre 2020

ARSEP: Working Visits


 

To facilitate exchanges between clinical centres and/or laboratories involved in MS. Travel may be within, to, or from France.

  • The training period can be up to 6 months.
  • Funding requests for up to 6.000 € to cover travel and accommodation are permitted.

Deadline: No deadline - throughout the year

https://www.arsep.org/fr/220-calls-for-proposals.html

https://www.arsep.org/library/media/other/Scientifique/Regulation-Working-visits-Travel-Grants-website.pdf

jeudi 03 décembre 2020

The American Parkinson Disease Association (APDA): Research Grants: Academic Year 2020-2021


Award:

One year grants up to a maximum of $75,000 will be awarded to research scientists (MD, MD/PhD, or PhD). The same investigator can reapply the following year to be considered for a second consecutive year of funding.

Goal:

APDA Research Grants are intended to support basic or applied research aimed at reducing the burden of Parkinson’s disease.  The APDA seeks to promote the entry of new investigators in to the field of Parkinson research, as well as to support important new ideas in the field worthy of investigation.

Eligibility:

All research scientists in the field of Parkinson’s research can apply, but the selection committee will more favorably consider researchers who are new to the field of Parkinson’s disease.

Deadline: 03/12/2020

Funding is not to be used for:

    Indirect costs.

    Institutional overhead.

    Salary for the principal investigator higher than $50,000.

    Travel expenses.

    Publication costs higher than $1,000.

    Equipment costs higher than $8,000.

https://www.apdaparkinson.org/research/research-opportunities/grants/

https://www.apdaparkinson.org/research/

vendredi 01 janvier 2021

European Brain Research Area consortium (EBRA): Call for clusters



The EBRA consortium is launching a Call for Clusters to promote co-operation and exchange between brain research projects and networks, and thus enable or enhance international collaboration and the emergence of development of clusters in all areas of brain research.

A cluster is understood as an association of research projects that can be directed towards basic research, clinical research and/or methodological approaches under a common topic, and disease and/or thematic area.

The individual members of a cluster application should be complementary.

The cluster formation should lead to a step-wise change in the landscape of that research area and should demonstrate a clear added-value in the collaboration/cooperation over individual projects including, but not limited to, sharing of resources (models, databases, diagnostics etc.), harmonisation of data, sharing of specific know-how and/or innovative technologies, etc.

The EBRA call for cluster is an open call until 1 January 2021.

Deadlines

1 June 2019
1 January 2020
1 June 2020
1 January 2021

More information: https://www.ebra.eu/Call4Clusters/